EyePoint, Inc. (EYPT) Stock Analysis

EyePoint's lead candidate, DURAVYU (vorolanib delivered via the company's bioerodible Durasert E technology), is in Phase 3 pivotal trials for wet age-related macular degeneration — the LUGANO and LUCIA studies, which fully enrolled over 900 combined patients by July 2025 with data expected beginning mid-2026 — and separate Phase 3 trials for diabetic macular edema (COMO and CAPRI) that dosed their first patient in February 2026. The company has no approved products or product revenue and is preparing a Northbridge, Massachusetts manufacturing facility for a potential U.S. commercial launch.

DURAVYU combines vorolanib, an in-licensed tyrosine kinase inhibitor that blocks all VEGF receptor isoforms plus PDGF and IL-6/JAK1 signaling, with Durasert E, a bioerodible intravitreal insert technology already validated across four FDA-approved non-erodible Durasert products administered to thousands of patient eyes. The wet AMD and DME Phase 3 programs are both randomized, aflibercept-controlled non-inferiority trials built on positive Phase 2 results (DAVIO 2 and VERONA, respectively), with patients re-dosed every six months; if the wet AMD program succeeds, EyePoint plans to file an initial NDA on 56-week data followed by a supplemental NDA on two-year safety data. Beyond DURAVYU, EyePoint's only other pipeline asset, EYP-2301 (razuprotafib, a TIE-2 agonist also formulated in Durasert E), remains in preclinical toxicity and pharmacokinetic testing, so essentially all near-term commercial value depends on DURAVYU's two ongoing Phase 3 programs succeeding.